Citicoline, also called CDP-choline, is a compound that the body's cells make from choline. It is a step on the main route for making phosphatidylcholine, a fat that cell membranes are built from. Supplements contain citicoline made by chemical synthesis or by fermentation with microbes. Cognizin is a brand of citicoline from Kyowa Hakko Bio.
Terms and sources
- CDP-choline
- Short for cytidine diphosphocholine. The EU specification describes it as made of cytosine, ribose, pyrophosphate and choline. Commission Implementing Regulation (EU) 2017/2470, Union list of novel foods.
- main route
- Phosphatidylcholine can be made from dietary choline through the CDP-choline pathway. Linus Pauling Institute.
- fermentation with microbes
- The EU specification covers both kinds, with the same purity limits. Commission Implementing Regulation (EU) 2017/2470, Union list of novel foods.
- Cognizin
- Named as the citicoline source in a 2021 trial: Nakazaki et al., Journal of Nutrition, 2021.
Citicoline in the body
Cell membranes are built largely from phosphatidylcholine. The body makes phosphatidylcholine from choline, with citicoline as one step. Choline makes up about 21% of citicoline by weight.
Terms and sources
- phosphatidylcholine
- Phosphatidylcholine makes up about 95% of the choline in body tissues. Linus Pauling Institute.
- one step
- The Linus Pauling Institute writes: “This phospholipid can be synthesized from dietary choline via the cytidine diphosphocholine (CDP-choline) pathway.”
- about 21%
- Our calculation from molecular weights: choline 104.17; citicoline 488.32, from the EU specification.
Citicoline taken by mouth is split into choline and cytidine, which are absorbed. In a study of 6 healthy adults, less than 1% of a 300 mg dose appeared in stool. Blood radioactivity peaked about 1 hour after the dose and again at 24 hours. Most of the dose left the body in exhaled carbon dioxide, and less in urine.
Terms and sources
- split into choline and cytidine
- In the gut wall and liver. Gareri et al., Clinical Interventions in Aging, 2015 (review).
- 6 healthy adults
- One dose of radiolabeled citicoline, with stool collected for 5 days. Dinsdale et al., Pharmacokinetics of 14C CDP-choline, Arzneimittel-Forschung, 1983.
- exhaled carbon dioxide
- The authors describe both routes and say the first predominated. Dinsdale et al., Pharmacokinetics of 14C CDP-choline, 1983.
Where citicoline comes from
Cells make citicoline themselves on the way to phosphatidylcholine. For supplements, citicoline is made by chemical synthesis or by fermentation with microbes. The EU specification requires at least 98% citicoline in the dry matter.
Terms and sources
- on the way to phosphatidylcholine
- Linus Pauling Institute.
- fermentation with microbes
- The EU specification lists synthetic citicoline and citicoline made with a genetically modified strain of E. coli. Both meet the same specification. Commission Implementing Regulation (EU) 2017/2470, Union list of novel foods.
- at least 98%
- Assay value of the dry matter. Commission Implementing Regulation (EU) 2017/2470, Union list of novel foods.
Citicoline is also given as a drug, by mouth or by injection.
Terms and sources
- as a drug
- The 2015 review by Gareri et al. writes: “When it is introduced as a drug, it can be called citicoline.”
Daily amounts and the upper limit
The trial on this page used 500 mg of citicoline a day for 12 weeks.
Terms and sources
- 500 mg
- Two 250 mg capsules with breakfast, for 12 weeks (Nakazaki 2021).
In the EU, a 2014 European Commission decision authorized citicoline for adults. It covers food supplements up to 500 mg a day and foods for special medical purposes. The decision says EFSA found citicoline "safe under the proposed uses and use levels". The decision adds: "EFSA also considered that citicoline may interact with specific medicines and should therefore not be administered together with those medicines."
Terms and sources
- 2014 European Commission decision
- Commission Implementing Decision 2014/423/EU, Article 1 and recitals 5 and 7. Food supplements: up to 500 mg a day. Foods for special medical purposes: up to 250 mg per serving and 1,000 mg a day. Not for foods for children. An EU decision, not an FDA review.
- The decision adds
- Commission Implementing Decision 2014/423/EU, recitals.
A 2015 review of citicoline reports occasional digestive upset and restlessness in the first days of use, especially after injection. It also lists occasional short-lived headache, tingling and numbness. The review states: "In 2,817 patients of all ages, but with a predominance of patients aged between 60 and 80 years old who had different neurological conditions, only 5.01% of the patients experienced side effects, mostly digestive intolerance. However, in no case, treatment had to be interrupted." It adds that no serious side effects have been reported at 500 mg to 2 g a day. The review also reports that citicoline can change how much levodopa, a prescription medicine, a person needs. This is a summary by reviewers, not a limit set by a regulator. If you take levodopa or any other prescription medicine, talk to your doctor or pharmacist before using citicoline.
Terms and sources
- A 2015 review
- Gareri et al., Clinical Interventions in Aging, 2015 (review). The authors report no conflicts of interest; the review has no funding section. A 2015 correction adds a source credit to one figure; the text quoted here is unchanged.
- especially after injection
- The review says “especially following parenteral administration”, that is, by injection or drip.
- The review states
- Quoted from the review's overview of safety, without reference numbers. Gareri et al., Clinical Interventions in Aging, 2015 (review).
- 500 mg to 2 g a day
- From the review's conclusion. By mouth, into a muscle or into a vein. Gareri et al., Clinical Interventions in Aging, 2015 (review).
- levodopa
- Gareri et al., 2015, overview of safety. The EU decision above does not name the medicines EFSA meant.
United States
The National Academies set daily amounts and an upper limit for choline, but not for citicoline. US labels list citicoline in mg per serving, without a percent Daily Value.
Terms and sources
- not for citicoline
- Citicoline has no Dietary Reference Intake of its own. National Academies, Dietary Reference Intakes summary tables.
- percent Daily Value
- FDA has not set a Daily Value for citicoline. 21 CFR 101.36.
In 69 US labels with citicoline as the only ingredient, 51 list 250 mg per serving. The others list 300 mg to 1 g per serving; 11 list more than 500 mg.
Terms and sources
- 69 US labels
- NIH Dietary Supplement Label Database, including products no longer sold. The only Supplement Facts row names citicoline, CDP-choline or Cognizin. 67 state mg and 2 state 1 g. A serving is not always a full day's amount.
- 300 mg to 1 g
- 650 mg is on 6 labels, 300 mg on 4 and 500 mg on 3. 1 g is on 4 labels and 600 mg on 1. We counted these.
In the same download, 507 labels list citicoline, and 79% have two or more rows in the Supplement Facts panel. Of them, 40% also list caffeine. 142 labels name the brand Cognizin, and 51 name a sodium salt of citicoline.
Terms and sources
- 507 labels
- Labels that name citicoline, CDP-choline, cytidine diphosphocholine or Cognizin in an ingredient or form line, including lines inside blends. Rows are the main rows of the panel; lines inside blends and Nutrition Facts lines are not counted. We counted these.
- 142 labels
- Named in an ingredient or form line. We counted these.
Published studies of citicoline
1 study from 1 report: it had mixed results.
Terms and sources
- 1 study from 1 report
- A daily dose of 500 mg of citicoline, for 12 weeks. Measures were computerized memory and attention tasks.
In 2024, EFSA, the EU food safety agency, assessed a proposed memory claim for citicoline. It weighed three trials in healthy middle-aged or older people with age-related memory complaints. One found a difference in episodic memory at 500 mg a day for 12 weeks. It found no difference in short-term or working memory. Another, at 1 g a day for 3 months, found no difference in episodic memory. EFSA drew no conclusions from the third. EFSA concluded that a cause-and-effect relationship with memory has not been established.
Terms and sources
- assessed a proposed memory claim
- EFSA Panel on Nutrition, Novel Foods and Food Allergens, EFSA Journal, 2024. The application came from Egde Pharma.
- has not been established
- EFSA's words: “a cause-and-effect relationship has not been established between the consumption of citicoline (CDP-Choline) inner salt and improvement, maintenance or reduced loss of memory in middle-aged or elderly adults encountering age-associated subjective memory impairment”.
The study in healthy adults, with our one-line summary.
We list the 10 largest studies by number of people randomized; 1 qualifies. Not listed: studies of people with a diagnosis or selected for a health condition, or after surgery. Also not listed: injections, infusions and eye drops, and studies in newborns, children and teenagers. Also not listed: trials that combined citicoline with a medicine, and an older study where some people took medicines. Also not listed: mixes with caffeine or other ingredients, and a comparison of two medicine tablets. Also not listed: trials whose random allocation we could not confirm, and a study without a comparison group. Also not listed: a trial with a published correction we could not read. Also not listed: a report whose participants may overlap with another and whose age range we could not read. Also not listed: two later reports that may describe the same 24 volunteers as that report.
Our one-line summary comes first. The original is on PubMed.
Show the study
100 adults over 50 took 500 mg citicoline or dummy capsules daily, 12 weeks; episodic and combined memory scores differed.
Trial · 100 people · 12 weeks · maker-funded
Nakazaki et al., 2021
Terms and sources
- 100 adults over 50
- Healthy volunteers aged 50–85. They were chosen for lower scores on a memory task: at least 1 standard deviation below young adults. 49 took citicoline and 51 the dummy; 99 finished.
- 500 mg citicoline
- Cognizin, two 250 mg capsules with breakfast.
- dummy capsules
- Capsules of microcrystalline cellulose, identical in color and size.
- episodic and combined memory scores differed
- Episodic memory (Paired Associates) rose 0.15 with citicoline vs 0.06 with the dummy. A combined memory score also differed: 3.78 vs 0.72. The main measure, Spatial Span, and 5 other tasks showed no significant difference. Mild events judged possibly related: 6 with citicoline and 2 with the dummy; none was serious. One person stopped citicoline because of a headache, judged possibly related. Changes are from the abstract. The table's unadjusted averages give slightly smaller changes with citicoline: 49 people at the start, 48 at the end.
- maker-funded
- Kyowa Hakko Bio, named as the source of Cognizin, sponsored and funded the trial and took part in its design. Two authors work for Kyowa Hakko Bio, one for Kyowa Hakko USA; two for Biofortis.
Study · Free full text · about 21 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
100 healthy adults aged 50 to 85 took 500 mg citicoline (Cognizin) or a dummy capsule daily, 12 weeks. They were chosen for lower scores on a memory task. Allocation was random and double-blind. Of 7 computerized tasks, episodic memory (Paired Associates) rose more with citicoline, and so did a combined memory score. The main measure, Spatial Span, and the other tasks showed no significant difference after correction for multiple tests. One person stopped citicoline because of a headache. Source: PMC full text (PMID 33978188). Funding: sponsored and funded by Kyowa Hakko Bio, named as the source of Cognizin.
Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.